Atlantic Healthcare Reports Results from Phase 1 Trial of Tablet for Crohns
September 27, 2018 08:00 ET | Atlantic Healthcare plc
CAMBRIDGE, UK, Sept. 27, 2018 (GLOBE NEWSWIRE) -- Oral Alicaforsen Appears Safe and Well-Tolerated via NEWMEDIAWIRE – Atlantic Healthcare plc (“Atlantic Healthcare” or “Company”), a specialist...
CRBP-300-196.png
Corbus Pharmaceuticals Announces Presentation of Three Abstracts and New Lenabasum Data at 2018 ACR Annual Meeting
September 14, 2018 08:05 ET | Corbus Pharmaceuticals Holdings, Inc.
Lenabasum open-label extension study interim data in systemic sclerosis and dermatomyositis to be presented  Norwood, MA, Sept. 14, 2018 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings,...
CRBP-300-196.png
Corbus Pharmaceuticals to Present at the Annual B. Riley FBR Healthcare Conference
August 23, 2018 08:05 ET | Corbus Pharmaceuticals Holdings, Inc.
Norwood, MA, Aug. 23, 2018 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a Phase 3 clinical-stage pharmaceutical company focused on the...
CRBP-300-196.png
Corbus Pharmaceuticals Reports 2018 Second Quarter Financial Results and Provides Business Update
August 08, 2018 09:00 ET | Corbus Pharmaceuticals Holdings, Inc.
Lenabasum has reached Phase 3 clinical stage in two orphan autoimmune indications: systemic sclerosis and dermatomyositis, affecting up to 200,000 patients in the USA, EU and JapanRecent long-term...
CRBP-300-196.png
Corbus Pharmaceuticals to Commence Phase 3 Study of Lenabasum for the Treatment of Rare Autoimmune Disease Dermatomyositis
July 25, 2018 09:20 ET | Corbus Pharmaceuticals Holdings, Inc.
Phase 3 study follows positive 16-weeks Phase 2 data and further improvement in efficacy outcomes with open-label extension dosing at six months12-month 150 subject study with ACR/EULAR 2016 Total...
CRBP-300-196.png
Corbus Pharmaceuticals Receives FDA Orphan Drug Designation for Lenabasum for the Treatment of Dermatomyositis
July 20, 2018 09:20 ET | Corbus Pharmaceuticals Holdings, Inc.
– Dermatomyositis is a rare chronic systemic autoimmune disease characterized by inflammation of muscles and skin – DM affects ~80,000 in the US, EU and Japan and has a 5-year mortality rate as high...
CRBP-300-196.png
Corbus Pharmaceuticals Appoints Former Director of FDA Office of New Drugs John K. Jenkins, MD to Board of Directors
June 06, 2018 07:05 ET | Corbus Pharmaceuticals Holdings, Inc.
– Distinguished 25-year career serving at the U.S. Food and Drug Administration, including 15 years of senior leadership in CDER and OND – – Appointment brings regulatory experience to the Board of...
CRBP-300-196.png
Corbus Pharmaceuticals to Present at the Jefferies 2018 Global Healthcare Conference
May 24, 2018 08:00 ET | Corbus Pharmaceuticals Holdings, Inc.
- Live audio presentation and webcast on Wednesday, June 6th at 9:00 a.m. EDT - Norwood, MA, May 24, 2018 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or...
CRBP-300-196.png
Corbus Pharmaceuticals Adds Two Key Executives to Lead its Regulatory and CMC Operations
May 22, 2018 08:00 ET | Corbus Pharmaceuticals Holdings, Inc.
— Robert Discordia, Ph.D., named Vice President, Pharmaceutical Development & Manufacturing —    — Ross Lobell named Vice President, Regulatory Affairs — Norwood, MA, May 22, 2018 (GLOBE...
CRBP-300-196.png
Corbus Pharmaceuticals Announces Acceptance of Three Abstracts for Presentation at EULAR 2018 Annual Meeting
May 15, 2018 08:00 ET | Corbus Pharmaceuticals Holdings, Inc.
- Data from Phase 2 one-year open-label extension of lenabasum in systemic sclerosis and 6-month open-label extension data in dermatomyositis studies to be presented -  Norwood, MA, May 15,...